136 related articles for article (PubMed ID: 16019760)
1. Molecular prostate cancer pathology: current issues and achievements.
Schalken JA; Bergh A; Bono A; Foster C; Gospadarowicz M; Isaacs WB; Rubin M; Schröder F; Tribukait B; Tsukamotot T; Wiklund P
Scand J Urol Nephrol Suppl; 2005 May; (216):82-93. PubMed ID: 16019760
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of molecular biomarkers in prostate cancer detection.
Dumache R; Miclea F; Bumblăcilă B; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):470-5. PubMed ID: 20700989
[TBL] [Abstract][Full Text] [Related]
3. Applicability of biomarkers in the early diagnosis of prostate cancer.
Hessels D; Verhaegh GW; Schalken JA; Witjes JA
Expert Rev Mol Diagn; 2004 Jul; 4(4):513-26. PubMed ID: 15225099
[TBL] [Abstract][Full Text] [Related]
4. Quantitative multi-gene expression profiling of primary prostate cancer.
Schmidt U; Fuessel S; Koch R; Baretton GB; Lohse A; Tomasetti S; Unversucht S; Froehner M; Wirth MP; Meye A
Prostate; 2006 Oct; 66(14):1521-34. PubMed ID: 16921506
[TBL] [Abstract][Full Text] [Related]
5. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue.
Bialkowska-Hobrzanska H; Driman DK; Fletcher R; Harry V; Razvi H
Can J Urol; 2006 Feb; 13(1):2967-74. PubMed ID: 16515751
[TBL] [Abstract][Full Text] [Related]
6. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
Cho KS; Oh HY; Lee EJ; Hong SJ
Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
[TBL] [Abstract][Full Text] [Related]
7. The end of the road for prostate specific antigen testing?
Nna E
Niger J Clin Pract; 2013; 16(4):407-17. PubMed ID: 23974730
[TBL] [Abstract][Full Text] [Related]
8. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for prostate cancer.
Leman ES; Getzenberg RH
J Cell Biochem; 2009 Sep; 108(1):3-9. PubMed ID: 19507229
[TBL] [Abstract][Full Text] [Related]
10. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
11. Urinary biomarkers for prostate cancer: a review.
Hessels D; Schalken JA
Asian J Androl; 2013 May; 15(3):333-9. PubMed ID: 23524531
[TBL] [Abstract][Full Text] [Related]
12. Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study.
Pipinikas CP; Nair SB; Kirby RS; Carter ND; Fenske CD
Biomarkers; 2007; 12(5):541-57. PubMed ID: 17701752
[TBL] [Abstract][Full Text] [Related]
13. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
[TBL] [Abstract][Full Text] [Related]
14. Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues.
Li SS
Kaohsiung J Med Sci; 1996 Aug; 12(8):441-7. PubMed ID: 8774111
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.
Liu AJ; Furusato B; Ravindranath L; Chen YM; Srikantan V; McLeod DG; Petrovics G; Srivastava S
J Zhejiang Univ Sci B; 2007 Dec; 8(12):853-9. PubMed ID: 18257117
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers.
Devaney J; Stirzaker C; Qu W; Song JZ; Statham AL; Patterson KI; Horvath LG; Tabor B; Coolen MW; Hulf T; Kench JG; Henshall SM; Pe Benito R; Haynes AM; Mayor R; Peinado MA; Sutherland RL; Clark SJ
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):148-59. PubMed ID: 21098650
[TBL] [Abstract][Full Text] [Related]
17. The epigenetic promise for prostate cancer diagnosis.
Van Neste L; Herman JG; Otto G; Bigley JW; Epstein JI; Van Criekinge W
Prostate; 2012 Aug; 72(11):1248-61. PubMed ID: 22161815
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
19. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
20. Urine markers in monitoring for prostate cancer.
Jamaspishvili T; Kral M; Khomeriki I; Student V; Kolar Z; Bouchal J
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):12-9. PubMed ID: 19652665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
